<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Choo Chee Kong -->
          <cik>0001970632</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>5</amendmentNo>
      <securitiesClassTitle>Ordinary Shares</securitiesClassTitle>
      <dateOfEvent>10/12/2026</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001873093</issuerCIK>
        <issuerCusips>
          <issuerCusipNumber>Y1R80M106</issuerCusipNumber>
        </issuerCusips>
        <issuerName>CytoMed Therapeutics Ltd</issuerName>
        <address>
          <com:street1>#08-22 ONE COMMONWEALTH</com:street1>
          <com:street2>1 COMMONWEALTH LANE</com:street2>
          <com:city>Singapore</com:city>
          <com:stateOrCountry>U0</com:stateOrCountry>
          <com:zipCode>149544</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Choo Chee Kong</personName>
          <personPhoneNum>65 6250 7738</personPhoneNum>
          <personAddress>
            <com:street1>#08-22 ONE COMMONWEALTH,</com:street1>
            <com:street2>1 COMMONWEALTH LANE</com:street2>
            <com:city>Singapore</com:city>
            <com:stateOrCountry>U0</com:stateOrCountry>
            <com:zipCode>149544</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001970632</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Choo Chee Kong</reportingPersonName>
        <fundType>PF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>U0</citizenshipOrOrganization>
        <soleVotingPower>928686.00</soleVotingPower>
        <sharedVotingPower>3773291.00</sharedVotingPower>
        <soleDispositivePower>928686.00</soleDispositivePower>
        <sharedDispositivePower>3773291.00</sharedDispositivePower>
        <aggregateAmountOwned>3003996.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>25.17</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Ordinary Shares</securityTitle>
        <issuerName>CytoMed Therapeutics Ltd</issuerName>
        <issuerPrincipalAddress>
          <com:street1>#08-22 ONE COMMONWEALTH</com:street1>
          <com:street2>1 COMMONWEALTH LANE</com:street2>
          <com:city>Singapore</com:city>
          <com:stateOrCountry>U0</com:stateOrCountry>
          <com:zipCode>149544</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item2>
        <filingPersonName>Choo Chee Kong</filingPersonName>
        <principalBusinessAddress>1 Commonwealth Lane #08-22, Singapore 149544</principalBusinessAddress>
        <principalJob>The Reporting Person is the Chairman of the Board and Director of the Issuer. The address of the Issuer is 1 Commonwealth Lane #08-22, Singapore 149544</principalJob>
        <hasBeenConvicted>No</hasBeenConvicted>
        <convictionDescription>No</convictionDescription>
        <citizenship>Singapore</citizenship>
      </item2>
      <item3>
        <fundsSource>PF; Between October 12, 2026 and October 15, 2026, the Reporting Person acquired an aggregate of 29,250 Ordinary Shares in open market purchases on the Nasdaq Capital Market for an aggregate purchase price of approximately $25,117.35, settled through the Reporting Person's brokerage account with personal funds.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>Mr. Choo Chee Kong has acquired all of the Ordinary Shares beneficially owned by him (1) in exchange for capital contributions to the Issuer or (2) through public purchases on the open market with his personal funds for investment purposes. The Reporting Person serves as Chairman of the Issuer and is a member of the board of directors of the Issuer and, as a result, may be asked to vote on or discuss matters related to items (a) through (j) of this Item 4 of Schedule 13D with representatives of the Issuer and others. Except as may be set forth herein, the Reporting Person has no current intention, plan or proposal with respect to items (a) through (j) of Item 4 of Schedule 13D.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows:

the Reporting Person beneficially owns 3,003,996 Ordinary Shares, representing 25.17% of the Issuer's outstanding shares as of the date hereof.

This includes: (1) 2,075,310 Ordinary Shares held indirectly through Glorious Finance Limited ("Glorious Finance"), in which Mr. Choo Chee Kong owns a 55% stake. As such, he is deemed to beneficially own 55% of the 3,773,291 shares held by Glorious Finance, while disclaiming ownership of the remainder. These shares were issued in exchange for capital contributions; (2) 194,112 Ordinary Shares held by EP Capital Inc. ("EP Capital"), which Mr. Choo Chee Kong is deemed to beneficially own. These shares were issued in exchange for capital contributions; and (3) 734,574 Ordinary Shares held directly by Mr. Choo Chee Kong, acquired with personal funds. The calculation is based on 11,934,908 Ordinary Shares outstanding as of the date hereof.</percentageOfClassSecurities>
        <numberOfShares>Please refer to Items 7-13 of the Cover Page. The Reporting Person has sole voting and dispositive power over 928,686 Ordinary Shares, and shared voting and dispositive power over 3,773,291 Ordinary Shares.</numberOfShares>
        <transactionDesc>Between October 12, 2026 and October 15, 2026, the Reporting Person acquired an aggregate of 29,250 Ordinary Shares of the Issuer in open market purchases on the Nasdaq Capital Market, effected through a brokerage account, at a weighted average price of $0.8587 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Ordinary Shares purchased at each separate price. All such transactions were conducted in compliance with the Issuer's insider trading policy and Rule 10b-5 under the Securities Exchange Act of 1934, as amended.</transactionDesc>
        <listOfShareholders>None</listOfShareholders>
        <date5PercentOwnership>N/A</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>The Reporting Person and the remaining shareholders of Glorious Finance Limited may be deemed to be acting as a "group" under Section 13(d)(3) as they share voting and dispositive power over the 3,773,291 Ordinary Shares of the Issuer. However, there is no formal agreement governing their voting or investment decisions.

Except as set forth herein, the Reporting Person has no contracts, arrangements, understandings, or relationships with respect to the Issuer's securities requiring disclosure under this Item 6.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>Except as set forth herein, there are no material agreements, contracts, arrangements, or understandings that require filing as exhibits under this Item 7.</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Choo Chee Kong</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Choo Chee Kong</signature>
          <title>Choo Chee Kong / Chairman and Director of CytoMed Therapeutics Limited</title>
          <date>10/16/2026</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
